JP6664638B1 - 新規プラズマローゲン誘導体 - Google Patents
新規プラズマローゲン誘導体 Download PDFInfo
- Publication number
- JP6664638B1 JP6664638B1 JP2019554942A JP2019554942A JP6664638B1 JP 6664638 B1 JP6664638 B1 JP 6664638B1 JP 2019554942 A JP2019554942 A JP 2019554942A JP 2019554942 A JP2019554942 A JP 2019554942A JP 6664638 B1 JP6664638 B1 JP 6664638B1
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- carbon atoms
- mmol
- cdcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 19
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 17
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 15
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 11
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Chemical group CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960001231 choline Drugs 0.000 claims abstract description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 4
- 229960000367 inositol Drugs 0.000 claims abstract description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 208000019736 Cranial nerve disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000014826 cranial nerve neuropathy Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 230000009390 immune abnormality Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 claims description 2
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 5
- 229940031098 ethanolamine Drugs 0.000 abstract description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract description 3
- 229960001153 serine Drugs 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 235000021003 saturated fats Nutrition 0.000 abstract 1
- 235000021081 unsaturated fats Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 44
- 239000011734 sodium Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000002158 endotoxin Substances 0.000 description 27
- 229920006008 lipopolysaccharide Polymers 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 238000003756 stirring Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 239000013256 coordination polymer Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 238000001816 cooling Methods 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 10
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 206010029260 Neuroblastoma Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000002442 prefrontal cortex Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 0 CC1(C)OC(CO*)CO1 Chemical compound CC1(C)OC(CO*)CO1 0.000 description 5
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 229940125833 compound 23 Drugs 0.000 description 5
- 229940125961 compound 24 Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
- 241000237509 Patinopecten sp. Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 235000020637 scallop Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 3
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 3
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 3
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- NOQXXYIGRPAZJC-SECBINFHSA-N [(2r)-oxiran-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H]1OC1 NOQXXYIGRPAZJC-SECBINFHSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940125876 compound 15a Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 210000005257 cortical tissue Anatomy 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- TYYCNSUODPEVQP-UHFFFAOYSA-N 8-[(4-fluorophenyl)sulfonylamino]-4-(3-pyridin-3-ylpropyl)octanoic acid Chemical compound C=1C=CN=CC=1CCCC(CCC(=O)O)CCCCNS(=O)(=O)C1=CC=C(F)C=C1 TYYCNSUODPEVQP-UHFFFAOYSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- -1 ether phospholipid Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000007277 glial cell activation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical group OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- KYLNAEAPFIBUCV-UHFFFAOYSA-N CC(C)(C)OC(NCCOP(OC)(OCC1(COCC(C)(C)CC(C)(C)COc2ccccc2)CC1)=O)=O Chemical compound CC(C)(C)OC(NCCOP(OC)(OCC1(COCC(C)(C)CC(C)(C)COc2ccccc2)CC1)=O)=O KYLNAEAPFIBUCV-UHFFFAOYSA-N 0.000 description 1
- QZSLPMGEZMVDNB-UHFFFAOYSA-N CC(C)(CC(C)(C)COc1ccccc1)COCC(CO)OCc1ccccc1 Chemical compound CC(C)(CC(C)(C)COc1ccccc1)COCC(CO)OCc1ccccc1 QZSLPMGEZMVDNB-UHFFFAOYSA-N 0.000 description 1
- ACRUKASLPDAHBC-UHFFFAOYSA-N CC(C)CC(C)(C)COc1ccccc1 Chemical compound CC(C)CC(C)(C)COc1ccccc1 ACRUKASLPDAHBC-UHFFFAOYSA-N 0.000 description 1
- DLRJIFUOBPOJNS-UHFFFAOYSA-N CCOc1ccccc1 Chemical compound CCOc1ccccc1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 description 1
- FAZZIMXGFSSKGO-UHFFFAOYSA-N C[O](CCCCCCCCN)=C Chemical compound C[O](CCCCCCCCN)=C FAZZIMXGFSSKGO-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WDCOJSGXSPGNFK-UHFFFAOYSA-N NCCCCCCCCO Chemical compound NCCCCCCCCO WDCOJSGXSPGNFK-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003215 anti-neuroinflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- HUZCTWYDQIQZPM-UHFFFAOYSA-N benzyl 2,2,2-trichloroethanimidate Chemical compound ClC(Cl)(Cl)C(=N)OCC1=CC=CC=C1 HUZCTWYDQIQZPM-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
すなわち、プラズマローゲンには、抗神経炎症作用とアミロイド生成予防効果があると考えられ、アルツハイマー病の予防又は改善(治療)への応用が示唆されている(非特許文献3参照)。
例えば、1999年にアルツハイマー病の脳(死体の脳)でエタノールアミン型プラズマローゲンが前頭葉と海馬で非常に有意に減少していることが報告され(非特許文献4参照)、さらに2007年にアルツハイマー病患者の血清でプラズマローゲンが減少していることが報告されている(非特許文献5参照)。
また、虚血性心疾患の患者群では、コリン型プラズマローゲンが正常コントロール群に比べて減少していることが報告されている(非特許文献6参照)。
そして、軽症アルツハイマー病、軽度認知障害のヒトを対象とした無作為化二重盲検臨床試験で上記ホタテ貝のヒモから抽出したプラズマローゲンを経口投与した結果、軽症アルツハイマー病で認知機能が改善されることが強く示唆されるという報告がなされている(非特許文献7参照)。
また、特許文献4においては、sn−1位をアセチル化した誘導体がドコサヘキサエン酸の良いキャリアであることが提案されており、ラットの急性脳卒中モデルに有効であることが報告されている(非特許文献9参照)。
本デザインは、プラズマローゲンそのものとしての機能、プラズマローゲンの前駆体としての機能、プラズマローゲンの効果を促進させる機能、あるいはドコサヘキサエン酸のキャリアとしての機能を有するいずれの化合物にも利用可能なものである。
[1]一般式(I)で示される化合物、そのラセミ体又はそれらの塩。
[2]Xが、酸素原子であることを特徴とする[1]記載の化合物、そのラセミ体又はそれらの塩。
[3]Yが、酸素原子、窒素原子又は硫黄原子であることを特徴とする[2]記載の化合物、そのラセミ体又はそれらの塩。
[4]Xが、窒素原子、硫黄原子又は炭素原子であることを特徴とする[1]記載の化合物、そのラセミ体又はそれらの塩。
[5]Yが、酸素原子、窒素原子、硫黄原子又は炭素原子であることを特徴とする[4]記載の化合物、そのラセミ体又はそれらの塩。
[6]R1a及びR1bが、飽和若しくは不飽和の脂肪族炭化水素基、芳香族基、又はこれらを組み合わせた基であることを特徴とする[1]〜[5]のいずれか記載の化合物、そのラセミ体又はそれらの塩。
[7][1]〜[6]のいずれか記載の化合物、そのラセミ体又はそれらの塩を有効成分として含むことを特徴とする医薬組成物。
[8]脳神経病、糖尿病、メタボリックシンドローム、虚血性心疾患、不眠症、感染症、及び免疫異常から選ばれる生体内プラズマローゲンレベルの低下に起因する疾患の予防又は改善用であることを特徴とする[7]記載の医薬組成物。
[9]認知症、パーキンソン病、うつ病、及び統合失調症から選ばれる脳神経病の予防又は改善用であることを特徴とする[8]記載の医薬組成物。
[10]認知症の予防又は改善用であることを特徴とする[9]記載の医薬組成物。
[11]認知症が、アルツハイマー型認知症であることを特徴とする[10]記載の医薬組成物。
本発明の新規化合物は、下記一般式(I)で示される化合物、そのラセミ体又はそれらの塩である。なお、一般式(I)中のグリセロール骨格の炭素原子は、置換基を有していてもよい。置換基としては、炭素数1〜4のアルキル基、炭素数1〜4のアルコキシ基等を挙げることができる。
R1におけるYは、酸素原子、窒素原子、硫黄原子又は炭素原子を表す。Xが酸素原子の場合、Yは、酸素原子、窒素原子又は硫黄原子であることが好ましい。
本発明の新規化合物(Xが酸素原子の場合)は、R1OH(R1a−Y−R1bOH)を出発原料として製造することができる。
出発原料であるR1OH(R1a−Y−R1bOH)に対して、下記構造で示される(2R)-Glycidyl Tosylateを反応させる。なお、(2R)-Glycidyl Tosylateに代えて、Epichlorohydrin等を用いることも可能である。
出発原料であるR1OH(R1a−Y−R1bOH)に対して、TsClを反応させて、R1OTsを得る(実施例3の工程2参照)。また、R1OHは、対応するカルボン酸(R1OOH)を還元して得ることができる(実施例3の工程1参照)。
本発明の医薬組成物は、上記一般式(I)で示される本発明の新規化合物、そのラセミ体又はそれらの塩を有効成分として含むことを特徴とする。本発明の医薬組成物は、薬学的に許容される他の成分を含んでいてもよい。
[工程1]
下記構造式で示される化合物2の製造
1H NMR (400 MHz, CDCl3): 7.80 (2H, d, J=8.7 Hz), 7.34 (2H, d, J=7.7 Hz), 7.05 (2H, d, J=8.7 Hz), 6.81 (2H, d, J=8.7 Hz), 4.10 (1H, dd, J=10.7, 5.8 Hz), 4.04 (1H, dd, J=10.7, 5.8 Hz), 4.0- 3.94 (1H, m), 3.93 (2H, t, J=6.7 Hz), 3.5-3.35 (4H, m), 2.56 (2H, t, J=7.8 Hz), 2.44 (3H, s), 2.36 (1H, d, J=5.8 Hz, OH), 1.9-1.7 (4H, m), 1.5-1.3 (10H, m), 0.89 (3H, t, J=6.8 Hz)
下記構造式で示される化合物3の製造
1H NMR (400 MHz, CDCl3): 7.78 (2H, d, J=8.7 Hz), 7.35- 7.25 (7H, m), 7.04 (2H, d, J=8.7 Hz), 6.80 (2H, d, J=8.7 Hz), 4.58-4.54 (2H, m), 4.20 (1H, dd, J=10.7, 4.4 Hz), 4.09 (1H, dd, J=10.7, 5.8 Hz), 3.92 (2H, t, J=6.8 Hz), 3.8-3.7 (1H, m), 3.5-3.4 (2H, m), 3.4-3.3 (2H, m), 2.52 (2H, t, J=7.5 Hz), 2.41 (3H, s), 1.8-1.7 (4H, m), 1.5-1.2 (10H, m), 0.88 (3H, t, J=7 Hz)
下記構造式で示される化合物4の製造
1H NMR (400 MHz, CDCl3): 7.4-7.25 (5H, m), 7.07 (2H, d, J=8.7 Hz), 6.81 (2H, d, J=8.7 Hz), 4.68 (2H, AB, J=11.6 Hz), 4.0-3.88 (2H, m), 3.8-3.4 (7H, m), 2.62 (2H, t, J=7.8 Hz), 2.14 (1H, t, J=8.5 Hz, OH), 1.9-1.7 (4H, m), 1.5-1.2 (10H, m), 0.89 (3H, t, J=7 Hz)
下記構造式で示される化合物5の製造
1H NMR (400 MHz, CDCl3): 7.4-7.2 (5H, m), 7.07 (2H, d, J=8.7 Hz), 6.81 (2H, d, J=8.2 Hz), 5.1-5.0 (1H, br.s, NH), 4.69 (2H, m), 4.3-4.0 (3H, m), 3.92 (2H, t, J=6.7 Hz) , 3.8-3.7 (5H, m), 3.58-3.48 (2H, m), 3.43 (2H, t, J=6.5 Hz), 3.4-3.3 (2H, m), 2.61 (2H, t, J=7.5 Hz), 1.9-1.7 (4H, m), 1.46-1.42 (9H, m) , 1.5-1.2 (19H, m) , 0.89 (3H, t, J=6.8 Hz)
下記構造式で示される化合物6の製造
1H NMR (400 MHz, CDCl3): 7.07 (2H, d, J=8.7 Hz), 6.82 (2H, d, J=8.7 Hz), 5.10 (1H, br. s, NH), 4.2-3.95 (5H, m), 3.95-3.90 (2H, m), 3.80 (3H, d, J=11.6 Hz) , 3.5-3.4 (6H, m) , 2.97 (1H, d like, OH), 2.61 (2H, t, J=7.7 Hz), 1.9-1.7 (4H, m), 1.45 (9H, s) , 1.4-1.2 (10H, m), 0.87 (3H, t, J=7.5 Hz)
下記構造式で示される化合物7a〜7dの製造
化合物6 (140 mg, 0.24 mmol) のCH2Cl2 (15 ml) 溶液にDMAP (68 mg, 0.56 mmol), EDC HCl (107 mg, 0.56 mmol), EPA (100 mg, 0.33 mmol)を加え、Ar雰囲気下、室温で一晩間撹拌した。溶媒を減圧留去し、残渣にAcOEtと水を加えて分液し、有機層をsatd. NaHCO3で洗浄し、MgSO4で乾燥後、ろ過し、溶媒を減圧留去して、残渣をPurif-Pack (SI 50, Size 60, AcOEt/Hex: 0→70%)で精製し、無色油状物として化合物7a (174 mg, y. 83%)を得た。
EPAに代えて、DHAを用いた以外は化合物7aの製造と同様にして、化合物7b (267 mg, y. 56%)を得た。
1H NMR (400 MHz, CDCl3): 7.09-7.05 (2H, m), 6.82-6.80 (2H, m), 5.4-5.3 (12H, m), 5.24- 5.15 (1H, m), 5.14-5.02 (1H, br. s, NH), 4.3-4.05 (4H, m), 3.92 (2H, t, J=6.7 Hz), 3.82-3.74 (3H, m), 3.6-3.5 (2H, m), 3.5-3.3 (4H, m), 2.9-2.8 (10H, m), 2.63-2.57 (2H, m), 2.41-2.39 (4H, m), 2.12- 2.03 (2H, m), 1.9-1.7 (4H, m), 1.44 (9H, s) , 1.4-1.2 (10H, m), 0.97 (3H, t, J=7.7 Hz) , 0.89 (3H, t, J=6.8 Hz)
EPAに代えて、Arachidonic Acidを用いた以外は化合物7aの製造と同様にして、化合物7c (168 mg, y. 84%)を得た。
1H NMR (400 MHz, CDCl3): 7.06 (2H, d, J=8.7 Hz), 6.81 (2H, d, J=8.7 Hz), 5.4-5.3 (8H, m), 5.2-5.0 (2H, m), 4.3-4.15 (2H, m), 4.15-4.05 (2H, m), 3.92 (2H, t, J=6 Hz), 3.77 (3H, dd, 10.6, 4.8 Hz), 3.6-3.5 (2H, m), 3.5-3.3 (4H, m), 2.85-2.75 (6H, m), 2.59 (2H, t, J=7 Hz), 2.37 (2H, t, J=7 Hz), 2.2-2.0 (2H, m), 1.9-1.7 (6H, m), 1.44 (9H, s) , 1.4-1.2 (18H, m), 0.88 (6H, m)
EPAに代えて、Linoleic Acidを用いた以外は化合物7aの製造と同様にして、化合物7d (52 mg, y. 26%)を得た。
1H NMR (400 MHz, CDCl3): 7.07 (2H, d, J=8.7 Hz), 6.81 (2H, d, J=8.7 Hz), 5.4-5.3 (4H, m), 5.2-5.0 (2H, m), 4.3-4.15 (2H, m), 4.15-4.05 (2H, m), 3.92 (2H, t, J=6.8 Hz), 3.77 (3H, dd, 10.6, 4.8 Hz), 3.6-3.5 (2H, m), 3.5-3.3 (4H, m), 2.77 (2H, t, J=6.8 Hz), 2.59 (2H, t, J=7 Hz), 2.34 (2H, t, J=7 Hz), 2.1-2.0 (4H, m), 1.9-1.7 (4H, m), 1.68-1.58 (2H, m), 1.44 (9H, s) , 1.4-1.2 (24H, m), 0.92- 0.86 (6H, m)
下記構造式で示される本発明の化合物REO-004、化合物REO-002、化合物REO-006、及び化合物REO-005の製造
化合物7a (170 mg, 0.20 mmol) のCH2Cl2 (1.5 ml) 溶液にMeCN (3 ml), iPrOH (3 ml), aq. NMe3 (4.7 ml, 0.33 mmol)を加え、Ar雰囲気下、室温で一晩撹拌した。溶媒を減圧留去し、PhMeで共沸した後、残渣をCHCl3 (1.5 ml)に溶かし、TFA (1.5 ml)を氷冷撹拌下に加えて、室温で1時間撹拌した。溶媒を減圧留去し、PhMeで共沸した後、残渣をPurif-Pack (SI 50, Size 60, MeOH/CHCl3: 0→30%)で精製し、wet solidとして化合物REO-004 (66.8 mg, y. 45%)を得た。
1H NMR (400 MHz, CDCl3): 8.45 (3H, br. s), 7.04 (2H, d, J=8.7 Hz), 6.78 (2H, d, J=8.7 Hz), 5.4-5.3 (10H, m), 5.2-5.1 (1H, m), 4.15-3.8 (6H, m), 3.6-3.3 (4H, m), 3.2-3.1 (2H, m), 2.9-2.7 (8H, m), 2.6-2.5 (2H, m), 2.4-2.3 (2H, m), 2.1-2.0 (4H, m), 1.9-1.6 (6H, m), 1.5-1.2 (10H, m), 0.96 (3H, t, J=7 Hz) , 0.88 (3H, t, J=6.8 Hz)
化合物7a (170 mg, 0.20 mmol)に代えて、化合物7b (265 mg, 0.30 mmol)を用いた以外は化合物REO-004の製造と同様にして、化合物REO-002 (88 mg, y. 40%)を得た。
1H NMR (400 MHz, CDCl3): 8.35 (3H, br. s), 7.04 (2H, d, J=7.7 Hz), 6.79 (2H, d, J=8.7 Hz), 5.45-5.25 (12H, m), 5.2-5.1 (1H, m), 4.2-3.8 (6H, m), 3.6-3.3 (4H, m), 3.2-3.1 (2H, m), 2.9-2.7 (10H, m), 2.6-2.5 (2H, m), 2.4-2.3 (4H, m), 2.1-1.7 (6H, m), 1.5-1.2 (10H, m), 0.96 (3H, t, J=7.7 Hz) , 0.88 (3H, t, J=6.8 Hz)
化合物7a (170 mg, 0.20 mmol)に代えて、化合物7c (165 mg, 0.19 mmol)を用いた以外は化合物REO-004の製造と同様にして、化合物REO-006 (99 mg, y. 69%)を得た。
1H NMR (400 MHz, CDCl3): 8.32 (3H, br. s), 7.04 (2H, d, J=8.7 Hz), 6.79 (2H, d, J=8.7 Hz), 5.4-5.3 (8H, m), 5.2-5.1 (1H, m), 4.2-3.8 (6H, m), 3.6-3.3 (4H, m), 3.2-3.1 (2H, m), 2.79 (2H, t, J=6.8 Hz), 2.6-2.5 (2H, m), 2.4-2.3 (2H, m), 2.1-1.6 (8H, m), 1.5-1.2 (18H, m), 0.9-0.8 (6H, m)
化合物7a (170 mg, 0.20 mmol) に代えて、化合物7d (49 mg, 0.058 mmol)を用いた以外は化合物REO-004の製造と同様にして、化合物REO-005 (31 mg, y. 73%)を得た。
1H NMR (400 MHz, CDCl3): 8.32 (3H, br. s), 7.04 (2H, d, J=8.7 Hz), 6.79 (2H, d, J=8.7 Hz), 5.4-5.3 (8H, m), 5.2-5.1 (1H, m), 4.2-3.8 (6H, m), 3.6-3.3 (4H, m), 3.2-3.1 (2H, m), 2.79 (2H, t, J=6.8 Hz), 2.6-2.5 (2H, m), 2.4-2.3 (2H, m), 2.1-1.6 (8H, m), 1.5-1.2 (18H, m), 0.9-0.8 (6H, m)
[工程1]
下記構造式で示される化合物10a及び化合物10bの製造
Mass EI(+):380
1H NMR (400 MHz, CDCl3): 7.79 (2H, d, J=7.9 Hz), 7.33 (2H, d, J=8.7 Hz), 7.29 (2H, d, J=8.7 Hz), 6.94 (1H, t, J=7.7 Hz), 6.88 (2H, d, J=7.7 Hz), 4.11-3.96 (5H, m), 3.65-3.59 (2H, m), 3.53-3.45 (2H, m), 2.46-2.42 (3H, m), 2.04-1.97 (2H, m)
Mass EI(+):408
1H NMR (400 MHz, CDCl3): 7.79 (2H, d, J=7.8 Hz), 7.34 (2H, d, J=8.7 Hz), 7.29 (2H, d, J=7.7 Hz), 6.93 (1H, t, J=7.7 Hz), 6.89 (2H, d, J=8.7 Hz), 4.09 (1H, dd, 10.6, 4.8 Hz), 4.04 (1H, dd, 10.6, 4.8 Hz), 4.02-3.9 (3H, m), 3.5-3.4 (4H, m), 2.43 (3H, s), 2.39 (1H, d, J=5.8 Hz, OH), 1.79 (2H, q, J=6.8 Hz), 1.7-1.4 (4H, m)
下記構造式で示される化合物11a及び化合物11bの製造
Mass EI(+):470
1H NMR (400 MHz, CDCl3): 7.76 (2H, d, J=7.7 Hz), 7.3-7.2 (9H, m), 6.94 (1H, t, J=7 Hz), 6.88 (2H, d, J=7.7 Hz), 4.56-4.54 (2H, m), 4.2-3.9 (3H, m), 3.8-3.7 (1H, m), 3.56 (2H, t, J=6.7 Hz), 3.5-3.44 (2H, m), 2.42 (3H, s), 2.02-1.93 (2H, m)
Mass EI(+):498
1H NMR (400 MHz, CDCl3): 7.77 (2H, d, J=7.7 Hz), 7.3-6.8 (12H, m), 4.6-4.55 (2H, m), 4.19 (1H, dd, J=10.2, 3.9 Hz), 4.08 (1H, dd, J=10.7, 5.8 Hz), 4.0-3.9 (2H, m), 3.8-3.7 (1H, m), 3.5-3.3 (4H, m), 2.45- 2.40 (3H, m), 1.8-1.7 (2H, m), 1.6-1.4 (4H, m)
下記構造式で示される化合物12a及び化合物12bの製造
Mass EI(+):316
1H NMR (400 MHz, CDCl3): 7.37-7.26 (7H, m), 6.94 (1H, t, J=7 Hz), 6.89 (2H, d, J=8.7 Hz), 4.64 (2H, AB, J=11.6 Hz), 4.1-4.0 (2H, m), 3.8-3.4 (7H, m), 2.1-2.0 (2H, m)
Mass EI(+):344
1H NMR (400 MHz, CDCl3): 7.4-6.8 (10H, m), 4.66 (2H, AB, J=11.6 Hz), 4.0-3.8 (3H, m), 3.8-3.4 (6H, m), 1.8-1.4 (6H, m)
下記構造式で示される化合物13a及び化合物13bの製造
Mass EI(+):553
1H NMR (400 MHz, CDCl3): 7.35-7.25 (10H, m), 6.93 (1H, t, J=7 Hz), 6.89 (2H, d, J=7.7 Hz), 5.1-5.0 (1H, br. s, NH), 4.7-4.6 (2H, m), 4.3-4.0 (6H, m), 3.8-3.5 (8H, m), 3.4-3.3 (2H, m), 2.05-2.0 (2H, m), 1.43 (9H, s)
Mass FAB(+):582
1H NMR (400 MHz, CDCl3): 7.4-6.8 (10H, m), 5.1-4.9 (1H, br. s, NH), 4.7-4.65 (2H, m), 4.3-4.0 (3H, m), 4.0-3.85 (2H, m), 3.8-3.7 (5H, m), 3.6-3.3 (6H, m), 1.8-1.5 (6H, m), 1.44 (9H, s)
下記構造式で示される化合物14a及び化合物14bの製造
Mass EI(+):463
1H NMR (400 MHz, CDCl3): 7.29 (2H, d, J=8.7 Hz), 6.94 (1H, t, J=7 Hz), 6.90 (2H, d, J=7.7 Hz), 5.15-5.05 (1H, br. s, NH), 4.2-4.0 (7H, m), 3.8-3.6 (3H, m), 3.67 (2H, t, J=6 Hz), 3.55-3.5 (2H, m), 3.45-3.35 (2H, m), 3.01 (1H, br. s, OH), 2.06 (2H, q, 5.8 Hz), 1.44 (9H, s)
Mass EI(+):491
1H NMR (400 MHz, CDCl3): 7.2-6.8 (5H, m), 5.10 (1H, br. s, NH), 4.2-3.9 (7H, m), 3.79 (3H, dd, 11.5, 3.8 Hz), 3.5-3.35 (6H, m), 1.8-1.5 (6H, m), 1.44 (9H, s)
下記構造式で示される化合物15a及び化合物15bの製造
Mass FAB(+):774.5
1H NMR (400 MHz, CDCl3): 7.3-7.2 (2H, m), 7.0-6.8 (3H, m), 5.5-5.3 (12H, m), 5.2-5.0 (2H, m), 4.2-4.0 (6H, m), 3.8-3.7 (3H, m), 3.7-3.5 (4H, m), 3.4-3.3 (2H, m), 2.9-2.8 (8H, m), 2.5-2.3 (6H, m), 2.1-2.0 (4H, m), 1.44 (9H, s), 0.97 (3H, t, J=7 Hz)
1H NMR (400 MHz, CDCl3): 7.2-6.8 (5H, m), 5.4-5.3 (12H, m), 5.2-5.0 (2H, m), 4.2-4.0 (4H, m), 4.0-3.9 (3H, m), 3.8-3.7 (2H, m), 3.6-3.3 (6H, m), 2.9-2.8 (10H, m), 2.41 (4H, m), 2.1-2.0 (2H, m), 1.8-1.7 (2H, m), 1.7-1.4 (4H, m), 1.44 (9H, s), 0.97 (3H, t, J=7.7 Hz)
下記構造式で示される本発明の化合物REO-007、及び化合物REO-003の製造
Mass FAB(+):660.4
1H NMR (400 MHz, CDCl3): 8.30 (3H, br. s), 7.3-7.2 (2H, m), 6.95-6.85 (3H, m), 5.4-5.3 (12H, m), 5.2-5.1 (1H, m), 4.1-3.9 (6H, m), 3.7-3.5 (4H, m), 3.2-3.0 (2H, m), 2.9-2.7 (10H, m), 2.4-2.3 (4H, m), 2.2-1.9 (4H, m), 0.97 (3H, t, J=7 Hz)
Mass FAB(+):688
1H NMR (400 MHz, CDCl3): 8.42 (3H, br. s), 7.2-6.8 (5H, m), 5.4-5.3 (12H, m), 5.2-5.1 (1H, m), 4.1-3.8 (6H, m), 3.6-3.3 (4H, m), 3.2-3.1 (2H, m), 2.9-2.8 (10H, m), 2.4-2.3 (4H, m), 2.1-2.0 (2H, m), 2.0-1.7 (2H, m), 1.7-1.3 (4H, m), 0.96 (3H, t, J=7.7 Hz)
[工程1]
下記構造式で示される化合物17の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ62.99, 32.74, 32.19, 32.15, 31.80, 29.71, 29.67, 29.26, 29.20, 29.18, 28.94, 28.84, 25.66, 22.63, 14.07
IR (ATR) 3345, 3264, 2919, 2848, 1459, 1378, 1278, 1225, 1189, 1130, 1050, 1021, 978, 748, 724 cm-1.
MS (ESI) m/z 279 (M+Na+).
HRMS (ESI) calcd for C16H34Na1O1S1 (M+Na+) 297.22281, found 297.22342.
下記構造式で示される化合物18の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ144.58, 133.24, 129.76, 127.84, 70.60, 32.20, 32.11, 31.80, 29.71, 29.60, 29.20, 29.18, 28.97, 28.94, 28.78, 28.73, 25.25, 22.62, 21.61, 14.07.
IR (ATR) 2918, 2851, 1597, 1468, 1355, 1307, 1173, 1097, 1049, 944, 816, 721, 665 cm-1.
MS (ESI) m/z 451 (M+Na+).
HRMS (ESI) calcd for C23H40Na1O3S2 (M+Na+) 451.23165, found 451.23225.
下記構造式で示される化合物19の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ 109.32, 74.74, 71.81, 66.92, 32.19, 32.15, 31.81, 29.72, 29.69, 29.52, 29.32, 29.21, 29.18, 28.95, 28.87, 26.76, 25.98, 25.41, 22.64,14.08.
IR (ATR) 2923, 2853, 1457, 1378, 1255, 1212, 1117, 1054, 845, 723 cm-1.
MS (ESI) m/z 411 (M+Na+).
HRMS (ESI) calcd for C22H44Na1O3S1 (M+Na+) 411.29088, found 411.29101.
下記構造式で示される化合物20の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ 72.48, 71.77, 70.40, 64.26, 32.19, 32.15, 31.80, 29.71, 29.66, 29.52, 29.28, 29.20, 29.18, 29.15, 28.94, 28.84, 26.00, 22.63, 14.07.
IR (ATR) 3388, 3308, 3226, 2919, 2849, 1459, 1437, 1123, 1085, 1033, 871, 727 cm-1.
MS (ESI) m/z 371 (M+Na+).
HRMS (ESI) calcd for C19H40Na1O3S1 (M+Na+) 371.25958, found 371.25964.
下記構造式で示される化合物21の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 178.57, 71.66, 71.40, 68.92, 65.40, 38.81, 32.19, 32.15, 31.80, 29.71, 29.67, 29.53, 29.30, 29.20, 29.17, 28.94, 28.85, 27.16, 25.99, 22.62, 14.07.
IR (ATR) 3451, 2924, 2853, 1730, 1458, 1396, 1365, 1283, 1159, 1120, 1035 cm-1.
MS (ESI) m/z 455 (M+Na+).
HRMS (ESI) calcd for C24H48Na1O4S1 (M+Na+) 455.31710, found 455.31721.
下記構造式で示される化合物22の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 178.36, 72.45, 71.69, 69.69, 66.19, 38.77, 32.20, 32.18, 31.81, 29.74, 29.72, 29.63, 29.35, 29.22, 29.19, 28.96, 28.89, 27.24, 26.05, 25.73, 22.64, 18.05, 14.08, -4.64, -4.82.
IR (ATR) 2926, 2854, 1732, 1460, 1282, 1251, 1119, 1004, 831, 776 cm-1.
MS (ESI) m/z 569 (M+Na+).
HRMS (ESI) calcd for C30H62Na1O4S1Si1 (M+Na+) 569.40358, found 569.40485.
下記構造式で示される化合物23の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 72.77, 71.71, 71.16, 65.09, 32.20, 32.16, 31.80, 29.73, 29.70, 29.61, 29.31, 29.21, 29.18, 29.17, 28.95, 28.87, 26.03, 25.78, 22.63, 18.10, 14.07, -4.61, -4.88
IR (ATR) 2925, 2853, 1462, 1251, 1115, 1048, 1004, 834, 776, 722, 669 cm-1.
MS (ESI) m/z 485 (M+Na+).
HRMS (ESI) calcd for C25H54Na1O3S1Si1 (M+Na+) 485.34606, found 485.34768.
下記構造式で示される化合物24の製造(方法1)
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 155.79, 83.39 (d, JC-P = 7.3 Hz, one diastereomer), 83.33 (d, JC-P = 8.3 Hz, the other diastereomer), 79.39, 71.95 (d, JC-P = 4.2 Hz), 71.72, 70.53 (d, JC-P = 8.3 Hz), 68.63 (d, JC-P = 6.2 Hz), 66.57 (brs), 40.97 (d, JC-P = 6.2 Hz), 32.20, 32.18, 31.81, 29.82, 29.80, 29.73, 29.71, 29.64, 29.37, 29.21, 28.96, 28.90, 28.38, 26.05, 25.77, 22.64, 18.13, 14.08, -4.74.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.67 (one diastereomer), -4.76 (the other diastereomer).
IR (ATR) 2926, 2854, 1732, 1460, 1282, 1251, 1119, 1004, 831, 776 cm-1.
MS (ESI) m/z 569 (M+Na+).
HRMS (ESI) calcd for C30H62Na1O4S1Si1 (M+Na+) 569.40358, found 569.40485.
下記構造式で示される化合物26の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 155.76, 83.89 (d, JC-P = 5.2 Hz, one diastereomer), 83.84 (d, JC-P = 6.2 Hz, the other diastereomer), 79.42, 71.66, 70.81, 69.37-69.29 (several peaks), 68.77 (d, JC-P = 6.2 Hz), 66.68 (brs), 40.83 (d, JC-P = 6.2 Hz), 32.13, 32.10, 31.75, 29.75, 29.71, 29.66, 29.63, 29.50, 29.28, 29.15, 29.13, 28.89, 28.82, 28.32, 25.95, 22.57, 14.03.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -3.89.
IR (ATR) 3348, 2924, 2854, 1713, 1522, 1458, 1366, 1250, 1171, 1117, 998 cm-1.
MS (ESI) m/z 650 (M+Na+).
HRMS (ESI) calcd for C30H62N1Na1O8P1S1 (M+Na+) 650.38314, found 650.38294.
下記構造式で示される化合物27の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 172.29, 155.73, 131.96, 129.31, 128.51, 128.24, 128.22, 128.19, 128.03, 128.01, 127.97, 127.80, 127.69, 126.95, 83.75 (d, JC-P = 7.3 Hz, one diastereomer), 83.67 (d, JC-P = 7.3 Hz, the other diastereomer), 79.39, 71.71, 70.82 (d, JC-P= 8.3 Hz), 68.30, 66.66, 65.40 (d, JC-P = 5.2 Hz), 40.89 (d, JC-P= 5.2), 34.06, 32.15, 32.12, 31.77, 29.75, 29.71, 29.69, 29.67, 29.49, 29.31, 29.18, 29.15, 28.92, 28.86, 28.34, 25.93, 25.59, 25.54, 25.49, 22.60, 20.51, 14.23, 14.05.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ -4.73 (one diastereomer), -4.83 (the other diastereomer).
IR (ATR) 3011, 2925, 2853, 1738, 1714, 1517, 1457, 1366, 1267, 1170, 1000 cm-1
MS (ESI) m/z 960 (M+Na+).
HRMS (ESI) calcd for C52H92N1Na1O9P1S1 (M+Na+) 960.61281, found 960.61212.
下記構造式で示される本発明の化合物KIT-007の製造
13C NMR (126 MHz; CDCl3; Me4Si) δ (contains some overlapping peaks) 172.44, 131.95, 129.25, 128.51, 128.25, 128.23, 128.21, 128.04, 128.01, 127.80, 126.96, 71.73, 71.04 (d, JC-P = 8.3 Hz), 68.60, 65.49, 62.94 (d, JC-P = 8.3 Hz), 40.28 (d, JC-P = 6.2 Hz), 34.08, 32.17, 32.15, 31.78, 29.69, 29.54, 29.38, 29.23, 29.19, 29.16, 28.93, 25.95, 25.59, 25.49, 22.61, 20.51, 14.24, 14.06.
31P NMR (202 MHz, CDCl3, External standard: 85 % H3PO4) δ 0.95.
IR (ATR) 3012, 2924, 2853, 1735, 1683, 1526, 1457, 1374, 1204, 1132, 1076, 1026 cm-1
MS (ESI) m/z 804 (M-HCl+Na+).
HRMS (ESI) calcd for C43H76N1Na1O7P1S1 (M-HCl+Na+) 804.49778, found 804.49691.
[試験1]
神経細胞株(マウス神経芽腫由来NEURO2A細胞及びヒト神経芽腫由来SH-SY5Y細胞)を10 % FBS(ウシ胎児血清)を含むDMEM培地で24時間培養した。その後、2 % FBSを含むDMEM培地で一晩(18時間)培養し、5 μg/mlのs-Pls(ホタテ由来Pls)、本発明の化合物REO-002、本発明の化合物REO-003でそれぞれ30分間処理し、細胞をウェスタンブロッティングアッセイに付した。その際、同量のタンパク質(50 μgのタンパク抽出物)を分析に付し、ERK (ERK1/2)のリン酸化(p-ERK)を比較した。
神経細胞株(ヒト神経芽腫由来SH-SY5Y細胞)を10 % FBS(ウシ胎児血清)を含むDMEM培地で24時間培養した。その後、2 % FBSを含むDMEM培地で一晩(18時間)培養し、1 μg/ml, 5 μg/mlの本発明の化合物REO-004〜REO-007でそれぞれ30分間処理し、細胞をウェスタンブロッティングアッセイに付した。その際、同量のタンパク質(50 μgのタンパク抽出物)を分析に付し、ERK (ERK1/2)のリン酸化(p-ERK)を比較した。
神経細胞株(マウス神経芽腫由来Neuro2A細胞)を10 % FBS(ウシ胎児血清)を含むDMEM培地で24時間培養した。その後、2 % FBSを含むDMEM培地で一晩(18時間)培養し、s-Pls(ホタテ由来Pls)及び本発明の化合物KIT-007の0.01 μg/ml〜5 μg/mlでそれぞれ20分間処理し、細胞をウェスタンブロッティングアッセイに付した。その際、同量のタンパク質(50 μgのタンパク抽出物)を分析に付し、ERK (ERK1/2) のリン酸化(p-ERK)及び全ERKを比較した。
試薬としては、(1)コントロールとしての生理食塩水、(2)生理食塩水に溶解したLPS(LPS: 250 μg/kg)、(3)〜(5)このLPS溶液に化合物KIT-007を所定濃度(低濃度(1mg/kg)、中濃度(10mg/kg)、高濃度(20mg/kg))で添加したものの計5種類を用いた。マウスの体重を8日間記録した(図5)。8日目にマウスを屠殺した。
その結果を図6〜8に示す。図6〜8に示すように、本発明の化合物KIT-007は、LPS誘発神経炎症に対する改善効果を有する。
試薬としては、(1)コントロールとしての生理食塩水、(2)生理食塩水に溶解したLPS(LPS: 250 μg/kg)、(3)このLPS溶液に化合物REO-002を低濃度(1mg/kg)添加したもの、(4)このLPS溶液に化合物REO-002を高濃度(5mg/kg)添加したものの計4種類を用いた。実験開始8日目に、無作為に各群から3匹のマウスを選び出し、屠殺して、経心腔的灌流を行い、脳を摘出し、免疫組織化学染色を行った。なお1日目及び4日目に、各群のマウスの一日当たりの飲水量を測定した。また、3日目に、各群のマウスの体重を測定した。
a. 全脳を4%パラホルムアルデヒドで固定し、スクロース脱水処理後OCTコンパウンド固定を行う。
b. 大脳皮質および海馬部位を20μmの厚さの切片にし、アジ化ナトリウムを加えたPBSで保存する。
c. 塩酸による抗原賦活化、トリス塩酸バッファーによる中和を経て、Iba-1(ミクログリア)、GFAP(アストロサイト)の染色、核染色を行う。
d. 蛍光顕微鏡で細胞数および細胞形状を確認する。
Claims (7)
- 一般式(I)で示される化合物、そのラセミ体又はそれらの塩。
- −R 2 は、R 2 COOHとした場合に、ω−3脂肪酸、ω−6脂肪酸、ω−7脂肪酸、ω−9脂肪酸、ω−10脂肪酸を示す1価の基を表すことを特徴とする請求項1記載の化合物、そのラセミ体又はそれらの塩。
- 請求項1又は2記載の化合物、そのラセミ体又はそれらの塩を有効成分として含むことを特徴とする医薬組成物。
- 脳神経病、糖尿病、メタボリックシンドローム、虚血性心疾患、不眠症、感染症、及び免疫異常から選ばれる生体内プラズマローゲンレベルの低下に起因する疾患の予防又は改善用であることを特徴とする請求項3記載の医薬組成物。
- 認知症、パーキンソン病、うつ病、及び統合失調症から選ばれる脳神経病の予防又は改善用であることを特徴とする請求項4記載の医薬組成物。
- 認知症の予防又は改善用であることを特徴とする請求項5記載の医薬組成物。
- 認知症が、アルツハイマー型認知症であることを特徴とする請求項6記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018086036 | 2018-04-27 | ||
JP2018086036 | 2018-04-27 | ||
PCT/JP2019/016638 WO2019208392A1 (ja) | 2018-04-27 | 2019-04-18 | 新規プラズマローゲン誘導体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002582A Division JP2020097580A (ja) | 2018-04-27 | 2020-01-10 | 新規プラズマローゲン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6664638B1 true JP6664638B1 (ja) | 2020-03-13 |
JPWO2019208392A1 JPWO2019208392A1 (ja) | 2020-05-28 |
Family
ID=68293573
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019554942A Active JP6664638B1 (ja) | 2018-04-27 | 2019-04-18 | 新規プラズマローゲン誘導体 |
JP2020002582A Pending JP2020097580A (ja) | 2018-04-27 | 2020-01-10 | 新規プラズマローゲン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002582A Pending JP2020097580A (ja) | 2018-04-27 | 2020-01-10 | 新規プラズマローゲン誘導体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210238208A1 (ja) |
EP (1) | EP3786170A1 (ja) |
JP (2) | JP6664638B1 (ja) |
KR (1) | KR20210005190A (ja) |
CN (1) | CN112166116B (ja) |
WO (1) | WO2019208392A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021221066A1 (ja) * | 2020-04-28 | 2021-11-04 | 株式会社レオロジー機能食品研究所 | 免疫機能亢進用組成物 |
WO2023027021A1 (ja) * | 2021-08-23 | 2023-03-02 | 株式会社レオロジー機能食品研究所 | 新規プラズマローゲン誘導体 |
AU2022394836A1 (en) * | 2021-11-22 | 2024-05-30 | Institute Of Rheological Function Of Food Co., Ltd. | Compound, racemate of said compound, salt of said compound or said racemate, composition, anti-inflammatory agent, therapeutic agent for dementia, and therapeutic agent for rett syndrome |
WO2023157948A1 (ja) * | 2022-02-21 | 2023-08-24 | Dic株式会社 | 経口用組成物 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63139188A (ja) * | 1986-11-13 | 1988-06-10 | ハフスルント・ニコメド・フアルマ・アクチエンゲゼルシヤフト | 混合置換された1、2‐ジーアシルーsn−グリセロ‐3‐ホスホコリンの一段階製造法 |
AT388165B (de) * | 1986-12-10 | 1989-05-10 | Chemie Linz Ag | Einstufiges verfahren zur herstellung von gemischt substituierten 1,2-di-acyl-sn-glycero-3- phosphocholinen |
WO1993021191A1 (en) * | 1992-04-16 | 1993-10-28 | Research Corporation Technologies, Inc. | Novel acylated phospholipid drugs |
JP2003012520A (ja) * | 2001-06-25 | 2003-01-15 | Yaizu Suisankagaku Industry Co Ltd | 抗酸化剤及びそれを含有する飲食品 |
DE10152376A1 (de) * | 2001-10-27 | 2003-05-15 | Carsten Schultz | Fluoreszente Phospholipase A¶2¶-Proben, ihre membran-permeablen Derivate und ihre Verwendung, sowie neue Reagenzien zur Herstellung der Proben |
JP2005529969A (ja) * | 2002-06-20 | 2005-10-06 | アイシー・ベック・リミテッド | 含硫黄ホスホリピド誘導体 |
JP2006232967A (ja) * | 2005-02-24 | 2006-09-07 | Umeda Jimusho:Kk | 複合脂質画分、それから単離されたヒト型スフィンゴミエリンとプラズマローゲンならびにこれらを含む機能性食品素材、医薬品素材および化粧品素材 |
WO2011083827A1 (ja) * | 2010-01-06 | 2011-07-14 | 株式会社レオロジー機能食品研究所 | 脳神経細胞新生剤 |
JP2016045112A (ja) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | エーテルリン脂質の定量方法 |
JP2016108466A (ja) * | 2014-12-08 | 2016-06-20 | 志郎 馬渡 | エーテルリン脂質およびその製造方法 |
JP2016111929A (ja) * | 2014-12-11 | 2016-06-23 | 株式会社 レオロジー機能食品研究所 | プラズマローゲンの定量方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080020472A1 (en) * | 2005-11-22 | 2008-01-24 | Frantz Biomarkers, Llc | Method for detecting an inflammatory disease or cancer |
EP2123281A1 (en) * | 2007-01-30 | 2009-11-25 | Tohoku University | Composition for prevention or treatment of disease associated with amyloidosis through inhibition of aggregation amyloid protein and through promotion of degradation of amyloid protein |
JP5483846B2 (ja) | 2008-09-10 | 2014-05-07 | 丸大食品株式会社 | 鳥類ムネ肉から得られる機能性素材及びその製造方法 |
TWI475989B (zh) | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法 |
JP2011136926A (ja) * | 2009-12-28 | 2011-07-14 | Hokkaido Univ | プラズマローゲンの分析方法 |
FR2979825B1 (fr) | 2011-09-13 | 2013-11-29 | Inst Nat Sciences Appliq | Phosphatidylcholines specifiques en tant que modulateurs de l'activite du facteur d'activation plaquettaire |
US9169280B2 (en) * | 2011-11-17 | 2015-10-27 | Phenomenome Discoveries Inc. | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
-
2019
- 2019-04-18 WO PCT/JP2019/016638 patent/WO2019208392A1/ja active Application Filing
- 2019-04-18 CN CN201980035092.8A patent/CN112166116B/zh active Active
- 2019-04-18 JP JP2019554942A patent/JP6664638B1/ja active Active
- 2019-04-18 KR KR1020207034208A patent/KR20210005190A/ko not_active Application Discontinuation
- 2019-04-18 US US17/050,905 patent/US20210238208A1/en active Pending
- 2019-04-18 EP EP19794041.4A patent/EP3786170A1/en active Pending
-
2020
- 2020-01-10 JP JP2020002582A patent/JP2020097580A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63139188A (ja) * | 1986-11-13 | 1988-06-10 | ハフスルント・ニコメド・フアルマ・アクチエンゲゼルシヤフト | 混合置換された1、2‐ジーアシルーsn−グリセロ‐3‐ホスホコリンの一段階製造法 |
AT388165B (de) * | 1986-12-10 | 1989-05-10 | Chemie Linz Ag | Einstufiges verfahren zur herstellung von gemischt substituierten 1,2-di-acyl-sn-glycero-3- phosphocholinen |
WO1993021191A1 (en) * | 1992-04-16 | 1993-10-28 | Research Corporation Technologies, Inc. | Novel acylated phospholipid drugs |
JP2003012520A (ja) * | 2001-06-25 | 2003-01-15 | Yaizu Suisankagaku Industry Co Ltd | 抗酸化剤及びそれを含有する飲食品 |
DE10152376A1 (de) * | 2001-10-27 | 2003-05-15 | Carsten Schultz | Fluoreszente Phospholipase A¶2¶-Proben, ihre membran-permeablen Derivate und ihre Verwendung, sowie neue Reagenzien zur Herstellung der Proben |
JP2005529969A (ja) * | 2002-06-20 | 2005-10-06 | アイシー・ベック・リミテッド | 含硫黄ホスホリピド誘導体 |
JP2006232967A (ja) * | 2005-02-24 | 2006-09-07 | Umeda Jimusho:Kk | 複合脂質画分、それから単離されたヒト型スフィンゴミエリンとプラズマローゲンならびにこれらを含む機能性食品素材、医薬品素材および化粧品素材 |
WO2011083827A1 (ja) * | 2010-01-06 | 2011-07-14 | 株式会社レオロジー機能食品研究所 | 脳神経細胞新生剤 |
JP2016045112A (ja) * | 2014-08-25 | 2016-04-04 | 株式会社 レオロジー機能食品研究所 | エーテルリン脂質の定量方法 |
JP2016108466A (ja) * | 2014-12-08 | 2016-06-20 | 志郎 馬渡 | エーテルリン脂質およびその製造方法 |
JP2016111929A (ja) * | 2014-12-11 | 2016-06-23 | 株式会社 レオロジー機能食品研究所 | プラズマローゲンの定量方法 |
Non-Patent Citations (3)
Title |
---|
LI RUOXIN, ET AL.: "Sulfur-substituted phosphatidylethanolamines", JOURNAL OF ORGANIC CHEMISTRY, vol. Vol.58(7), JPN6019017521, 1993, pages 1952 - 1954, ISSN: 0004151402 * |
ROZIN A. E., ET AL.: " Mass spectrometry of lipids with an ether bond. Mass spectrometry of alkyl type glycerophospholipi", BIOORGANICHESKAYA KHIMIYA, vol. Vol.3(3), JPN6019017520, 1977, pages 397 - 401, ISSN: 0004151401 * |
WICHMANN OLIVER, ET AL.: " Probing phospholipase A2 with fluorescent phospholipid substrates", CHEMBIOCHEM, vol. Vol.8(13), JPN6019017522, 2007, pages 1555 - 1569, ISSN: 0004151403 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210005190A (ko) | 2021-01-13 |
JPWO2019208392A1 (ja) | 2020-05-28 |
CN112166116A (zh) | 2021-01-01 |
JP2020097580A (ja) | 2020-06-25 |
US20210238208A1 (en) | 2021-08-05 |
EP3786170A4 (en) | 2021-03-03 |
EP3786170A1 (en) | 2021-03-03 |
WO2019208392A1 (ja) | 2019-10-31 |
CN112166116B (zh) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6664638B1 (ja) | 新規プラズマローゲン誘導体 | |
CN104768541B (zh) | Atx调节剂 | |
KR20080086546A (ko) | 신경병증성 통증의 치료 방법 | |
JP5896472B2 (ja) | PKC−ε活性化剤 | |
JP2001527058A (ja) | ノイラミニダーゼ阻害剤として有用な置換シクロペンタン及びシクロペンテン化合物 | |
WO2016007762A1 (en) | Compositions and methods for the repair of myelin | |
TW201034662A (en) | Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging | |
JP2011503057A (ja) | 化粧品において,食品サプリメントとして,または医薬品として用いるための脂質化合物 | |
RU2584163C2 (ru) | Производное транс-2-деценовой кислоты и содержащее его фармацевтическое средство | |
WO2016130417A1 (en) | Omega-3 fatty acid prodrug compounds and uses thereof | |
JP5077893B2 (ja) | 環状ホスファチジン酸誘導体を含む鎮痛剤 | |
EP1095050A1 (de) | Phosphororganische verbindungen und ihre verwendung | |
JPH07509458A (ja) | 抗過血糖症および/または抗肥満活性を有するホスホン化アリールエタノールアミン化合物 | |
EP0543780A2 (de) | Neue Aminoalkanphosphinsäuren und ihre Salze | |
WO1993011138A1 (en) | Amine derivatives containing a phosphonic, phosphonous or phosphinic acid moiety | |
DE69918433T2 (de) | C11-oxymyl- and hydroxylamino-prostaglandine und ihre anwendung als arzneimittel | |
RU2593260C2 (ru) | Производное бутилфталида, способ его получения и применение | |
US20080032950A1 (en) | Neurologically-Active Compounds | |
WO2010076418A1 (fr) | Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation | |
JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
WO2011065480A1 (ja) | 神経細胞死抑制剤 | |
WO2023027021A1 (ja) | 新規プラズマローゲン誘導体 | |
JP6864899B2 (ja) | 損傷治療剤 | |
CA2384525C (en) | Thienylhydrazon with digitalis-like properties (positive inotropic effects) | |
CN112218878A (zh) | Ntcp抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191004 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20191004 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20191030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200124 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6664638 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |